Breast CA nodal mets more common with certain mutations

Breast CA nodal mets more common with certain mutations
Lymph node metastases are more common in breast cancers with mutations in a cellular signaling pathway associated with growth, according to a study published online July 24 in JAMA Surgery.

(HealthDay)—Lymph node metastases are more common in breast cancers with mutations in a cellular signaling pathway associated with growth, according to a study published online July 24 in JAMA Surgery.

Cory A. Donovan, M.D., from the Oregon Health & Science University in Portland, and colleagues analyzed 30 invasive ductal breast cancers (stages IA through IIIB) for mutations in the AKT1, HRAS, and PIK3CA genes in stem and progenitor cells and their association with various demographic and clinical factors.

The researchers found that 10 tumors had mutations. The presence of lymph node was significantly more common when were present (90 versus 20 percent).

"Tumors in which breast cancer stem and progenitor cells have defects in PI3K/Akt signaling are significantly more likely to manifest nodal metastases," Donovan and colleagues conclude. "These oncogenic defects may be missed by gross molecular testing of the tumor and are markers of more aggressive breast cancer."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Biomarker in aggressive breast cancer identified

8 hours ago

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, ...

MRI better detects recurrent breast cancer

9 hours ago

(HealthDay)—Single-screening breast magnetic resonance imaging (MRI) detects 18.1 additional cancers after negative findings with mammography and ultrasonography (US) per 1,000 women with a history of breast ...

Natural (born) killer cells battle pediatric leukemia

21 hours ago

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that ...

User comments